AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $763 | +151.8% | 14,510 | +35.7% | 0.00% | +100.0% |
Q2 2023 | $303 | +23.2% | 10,691 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $246 | -18.0% | 10,691 | 0.0% | 0.00% | -50.0% |
Q4 2022 | $300 | -99.9% | 10,691 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $302,000 | +27.4% | 10,691 | 0.0% | 0.00% | +100.0% |
Q2 2022 | $237,000 | -23.8% | 10,691 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $311,000 | -12.4% | 10,691 | -1.0% | 0.00% | 0.0% |
Q4 2021 | $355,000 | -28.7% | 10,796 | 0.0% | 0.00% | -50.0% |
Q3 2021 | $498,000 | -16.3% | 10,796 | 0.0% | 0.00% | -33.3% |
Q2 2021 | $595,000 | +6.6% | 10,796 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $558,000 | +19.2% | 10,796 | 0.0% | 0.00% | +50.0% |
Q4 2020 | $468,000 | +23.8% | 10,796 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $378,000 | -34.5% | 10,796 | 0.0% | 0.00% | -33.3% |
Q2 2020 | $577,000 | +50.7% | 10,796 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $383,000 | -25.8% | 10,796 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $516,000 | +47.4% | 10,796 | 0.0% | 0.00% | +50.0% |
Q3 2019 | $350,000 | -35.1% | 10,796 | 0.0% | 0.00% | -33.3% |
Q2 2019 | $539,000 | -50.8% | 10,796 | -33.5% | 0.00% | -57.1% |
Q1 2019 | $1,095,000 | +236.9% | 16,230 | +130.4% | 0.01% | +250.0% |
Q4 2018 | $325,000 | -40.4% | 7,044 | -0.3% | 0.00% | -33.3% |
Q3 2018 | $545,000 | -8.6% | 7,066 | -0.1% | 0.00% | -25.0% |
Q2 2018 | $596,000 | +3.1% | 7,075 | +0.1% | 0.00% | 0.0% |
Q1 2018 | $578,000 | +49.4% | 7,069 | +4.4% | 0.00% | +100.0% |
Q4 2017 | $387,000 | -10.8% | 6,769 | +4.1% | 0.00% | -33.3% |
Q3 2017 | $434,000 | +29.6% | 6,505 | +0.0% | 0.00% | +50.0% |
Q2 2017 | $335,000 | -7.2% | 6,504 | +5.2% | 0.00% | -33.3% |
Q1 2017 | $361,000 | +39.9% | 6,181 | -0.2% | 0.00% | +50.0% |
Q4 2016 | $258,000 | -20.1% | 6,194 | +1.3% | 0.00% | -33.3% |
Q3 2016 | $323,000 | +26.2% | 6,113 | +0.0% | 0.00% | +50.0% |
Q2 2016 | $256,000 | +4.5% | 6,110 | +1.4% | 0.00% | 0.0% |
Q1 2016 | $245,000 | -31.0% | 6,028 | +10.3% | 0.00% | -33.3% |
Q4 2015 | $355,000 | -7.8% | 5,465 | +0.1% | 0.00% | 0.0% |
Q3 2015 | $385,000 | -36.6% | 5,457 | -0.2% | 0.00% | -40.0% |
Q2 2015 | $607,000 | +38.9% | 5,466 | +18.0% | 0.01% | +25.0% |
Q1 2015 | $437,000 | – | 4,634 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BB BIOTECH AG | 2,719,998 | $155,502,000 | 4.38% |
Casdin Capital, LLC | 295,000 | $16,865,000 | 4.11% |
Opaleye Management Inc. | 130,000 | $7,432,000 | 2.38% |
Opus Point Partners Management, LLC | 28,704 | $1,641,000 | 1.42% |
Fernwood Investment Management, LLC | 27,550 | $1,575,000 | 0.84% |
Rhenman & Partners Asset Management AB | 100,000 | $5,717,000 | 0.77% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 760,116 | $43,456,000 | 0.65% |
Eventide Asset Management | 214,000 | $12,234,000 | 0.64% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 262,984 | $15,035,000 | 0.59% |
CAPITAL GUARDIAN TRUST CO | 663,089 | $37,909,000 | 0.54% |